- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07446322
En öppen, randomiserad, multicentrisk, fas 2-studie av FOLFIRI + Bevacizumab + Pelareorep jämfört med FOLFIRI + Bevacizumab för andrahandsbehandling av metastaserad, RAS-muterad, mikrosatellitstabil (MSS) kolorektalcancer
En öppen, randomiserad, multincentrisk, fas 2-studie av FOLFIRI + Bevacizumab + Pelareorep jämfört med FOLFIRI + Bevacizumab för andra linjens behandling av metastatisk, RAS-muterad, mikrosatellitstabil (MSS) kolorektalcancer
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Approximately 60 patients will be randomized 1:1 to the following study arms:
- Arm A: FOLFIRI + bevacizumab + pelareorep
- Arm B: FOLFIRI + bevacizumab The primary endpoint is ORR as assessed by the investigator per RECIST 1.1. OS, PFS, and assessment of the safety and tolerability of the study treatment combinations are secondary endpoints. The primary endpoint analysis will be performed after all patients have had at least one tumor assessment following initiation of study treatment or have progressed. The secondary endpoint analyses will take place at EOS.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Name: Reference Study ID Number: REO 033
- Telefonnummer: +1 (858) 247-7829
- E-post: REO-033@oncolytics.com
Studieorter
-
-
Alabama
-
Homewood, Alabama, Förenta staterna, 35209
- Rekrytering
- Central Alabama Research
-
Kontakt:
- Lorie Syzmela
- Telefonnummer: 205-949-1907
- E-post: lszymela@centralalabamaresearch.com
-
-
California
-
Beverly Hills, California, Förenta staterna, 90211
- Rekrytering
- Clinical Research Advisors (Beverly Hills)
-
Kontakt:
- Ali Muhammad, MD, MBA
- Telefonnummer: 310-432-8934
- E-post: AMuhammad@bhcancercenter.com
-
Encino, California, Förenta staterna, 91316
- Rekrytering
- Clinical Research Advisors (Encino)
-
Koreatown, California, Förenta staterna, 90020
- Rekrytering
- Clinical Research Advisors (Korea Town)
-
Los Angeles, California, Förenta staterna, 90033
- Rekrytering
- Clinical Research Advisors (Downtown LA)
-
Los Angeles, California, Förenta staterna, 90048
- Rekrytering
- Clinical Research Advisors (West Hollywood)
-
West Covina, California, Förenta staterna, 91790
- Rekrytering
- Clinical Research Advisors (West Covina)
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612
- Rekrytering
- Moffitt Cancer Center
-
Kontakt:
- Cheyenne Schneider
- Telefonnummer: 813-745-5166
- E-post: Cheyenne.Schneider@moffitt.org
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30302
- Rekrytering
- Emory Winship Cancer Institute
-
Kontakt:
- Kathleen Coleman
- Telefonnummer: 404-251-1278
- E-post: kathleen.marie.coleman@emory.edu
-
Kontakt:
- Armand Fernandez
- Telefonnummer: 404-778-8201
- E-post: armand.falqueza.fernandez@emory.edu
-
-
Idaho
-
Post Falls, Idaho, Förenta staterna, 83854
- Rekrytering
- Beacon Cancer Center
-
Kontakt:
- Kaitie Bean
- Telefonnummer: 204 208-755-2804
- E-post: kbean@yourbeaconclinic.com
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Rekrytering
- Northwestern Memorial Hospital
-
Kontakt:
- E-post: clinicaltrials@northwestern.edu
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46250
- Rekrytering
- Community Health Network
-
Kontakt:
- Mindy Thacker
- Telefonnummer: 317-621-4300
- E-post: MThacker@ecommunity.com
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Rekrytering
- Karmanos Cancer Institute
-
Kontakt:
- Taylor Brewer
- E-post: brewert@karmanos.org
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
- Rekrytering
- Washington University School of Medicine
-
Kontakt:
- Justin Stout
- Telefonnummer: 314-362-2582
- E-post: justinjstout@wustl.edu
-
-
New Jersey
-
Florham Park, New Jersey, Förenta staterna, 07932
- Rekrytering
- Summit Health Cancer Center
-
Kontakt:
- Michelle Mackenzie
- Telefonnummer: 973-436-1755
- E-post: mmackenzie@summithealth.com
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Rekrytering
- Rutgers Cancer Institute
-
Kontakt:
- Christian F Misdary
- Telefonnummer: 732-735-3626
- E-post: cm1344@cinj.rutgers.edu
-
-
Ohio
-
Canton, Ohio, Förenta staterna, 44718
- Rekrytering
- Gabrail Cancer Center
-
Kontakt:
- Carrie Smith
- Telefonnummer: 330-417-8231
- E-post: recruitment@gabrailcancercenter.com
-
Kontakt:
- Kimberly Roby
- Telefonnummer: 227 330-492-3345
- E-post: recruitment@gabrailcancercenter.com
-
Cincinnati, Ohio, Förenta staterna, 45219
- Rekrytering
- University of Cincinnati Medical Center
-
Colombus, Ohio, Förenta staterna, 43210
- Rekrytering
- Ohio State University
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- The University of Texas MD Anderson Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically confirmed cancer of the colon or rectum with documented metastasis
- Measurable disease per RECIST v. 1.1
- Not candidates for curative surgery or curative radiation
- Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin
- Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab
- Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non dMMR) tumor status per a standard local testing method
- Tumor confirmed to harbor a known RAS mutation per a standard local testing method
- ECOG performance status of 0 or 1
- Patients must have adequate hematological, renal, and hepatic function
- Female patients of childbearing potential must have a negative pregnancy test
- Life expectancy of at least 6 months
Exclusion Criteria:
- Undergone systemic chemotherapy, radiotherapy, or surgery, <4 weeks before study treatment
- Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment
- Prior treatment with irinotecan
- Symptomatic brain metastases
- Active autoimmune disease
- Receiving immunosuppressive or myelosuppressive medications
- Active, uncontrolled infections
- Known HIV infection or active hepatitis B or C that requires anti-viral treatment
- History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ
- History of allergy or known hypersensitivity to any of the study drugs, study drug classes,
- Uncontrolled or severe cardiac disease
- Received any vaccine within 28 days prior to first study treatment
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm A
|
Bevacizumab (5 mg/kg) IV infusion
Andra namn:
irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion pelareorep 4.5 x 10^10 TCID50 IV infusion |
|
Experimentell: Arm B
|
Bevacizumab (5 mg/kg) IV infusion
Andra namn:
irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Response Rate (ORR)
Tidsram: At week 8
|
Proportion of patients with complete response [CR], partial response [PR] assessed by the investigators and/or central reader according to RECIST v1.1 |
At week 8
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Survival (OS) -
Tidsram: From the date of randomization through long term follow up at two years
|
OS defined as the time from date of randomization to death from any cause |
From the date of randomization through long term follow up at two years
|
|
Progression Free Survival (PFS)
Tidsram: From randomization to objective progression or death from any cause, whichever occurs first, up to two years
|
Time from randomization to the date of investigator-determined objective progression (according to RECIST 1.1) or death from any cause, whichever occurs first. |
From randomization to objective progression or death from any cause, whichever occurs first, up to two years
|
|
Disease Control Rate (DCR)
Tidsram: From randomization to disease progression or death from any cause, whichever occurs first, up to two years
|
Overall DCR, defined as the number of patients with a best overall response of CR, PR, or SD according to RECIST v. 1.1 |
From randomization to disease progression or death from any cause, whichever occurs first, up to two years
|
|
Duration of Response (DOR)
Tidsram: From randomization to disease progression or death from any cause, whichever occurs first, up to two years
|
Time from documentation of the first CR or PR to the time of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death. |
From randomization to disease progression or death from any cause, whichever occurs first, up to two years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- REO 033
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .